Our Company

Our Company

Leadership

Derived from the expression 'securing health for all of us', Seqirus has public health protection at its core.
Learn more

At Seqirus, Corporate Responsibility is about conducting our business ethically and contributing to the economic, social and environmental well-being of our communities.
Learn more
Products
Key Customer Information
Careers

Our Company

NEWS

Media Contacts:

Canada

Polina Miklush
Mobile: +1 908 608 7170
Email: polina.miklush@seqirus.com

Seqirus news releases

COVID-19 Update

02 Apr 2020

Safeguarding our people and communities remains our top priority.

Read update

Seqirus announces Health Canada approval of first cell-based seasonal influenza vaccine

11 Dec 2019

/CNW/ - Seqirus, a global leader in influenza prevention, announced today that its cell-based quadrivalent influenza vaccine (QIVc) has received approval from Health Canada for use in people 9 years of age and older. Marketed as FLUCELVAX® QUAD, the vaccine offers protection against four influenza virus strains — A(H3N2), A(H1N1) and two B virus strains¹.